CliffBio
small molecule

TERIPARATIDE

TERIPARATIDE

Loss of exclusivity—loss of exclusivity
CompanyApotex →See this company's full patent-cliff portfolio

Drug detail

Brand nameTERIPARATIDE
Active ingredientTERIPARATIDE
Strength0.56MG/2.24ML (0.25MG/ML)
Dosage formSOLUTION
RouteSUBCUTANEOUS
ModalitySmall molecule
FDA approvalNovember 2023
Marketing statusRX

More from Apotex

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.